Anti-BRD4 Antibody Picoband®

Bromodomain-containing protein 4 is a protein that in humans is encoded by the BRD4 gene. The protein encoded by this gene is homologous to the murine protein MCAP, which associates with chromosomes during mitosis, and to the human RING3 protein, a serine/threonine kinase. Each of these proteins contains two bromodomains, a conserved sequence motif which may be involved in chromatin targeting. This gene has been implicated as the chromosome 19 target of translocation t (15;19) (q13; p13.1), which defines an upper respiratory tract carcinoma in young people. Two alternatively spliced transcript variants have been described.

A synthetic peptide corresponding to a sequence in the middle region of human BRD4, which shares 95% amino acid (aa) sequence identity with mouse BRD4.

Angiogenesis, Cancer, Cardiovascular, Developmental Biology, Growth Factors, Growth Factors/Hormones, Invasion/Microenvironment, Neural Stem Cells, Neurogenesis, Neurology Process, Neuroscience, Organogenesis, Signal Transduction, Stem Cells

Acts as a ligand for FGFR1, FGFR2, FGFR3 and FGFR4. Also acts as an integrin ligand which is required for FGF2 signaling. Binds to integrin ITGAV:ITGB3. Plays an important role in the regulation of cell survival, cell division, cell differentiation and cell migration. Functions as a potent mitogen in vitro. Can induce angiogenesis.

1. Choe, J., Lin, S., Zhang, W., Liu, Q., Wang, L., Ramirez-Moya, J., Du, P., Kim, W., Tang, S., Sliz, P., Santisteban, P., George, R. E., Richards, W. G., Wong, K.-K., Locker, N., Slack, F. J., Gregory, R. I. mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis. Nature 561: 556-560, 2018. 2. Crawford, N. P. S., Alsarraj, J., Lukes, L., Walker, R. C., Officewala, J. S., Yang, H. H., Lee, M. P., Ozato, K., Hunter, K. W. Bromodomain 4 activation predicts breast cancer survival. Proc. Nat. Acad. Sci. 105: 6380-6385, 2008. 3. Dawson, M. A., Prinjha, R. K., Dittmann, A., Giotopoulos, G., Bantscheff, M., Chan, W.-I., Robson, S. C., Chung, C., Hopf, C., Savitski, M. M., Huthmacher, C., Gudgin, E., and 15 others. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478: 529-533, 2011.

At -20°C for one year from date of receipt. After reconstitution, at 4°C for one month. It can also be aliquotted and stored frozen at -20°C for six months. Avoid repeated freezing and thawing.